Celltrion Nearly Triples Production Capability For Biosimilars In Anticipation Of Global Launches
This article was originally published in PharmAsia News
Executive Summary
SEOUL - South Korea's biosimilar front-runner Celltrion, Inc. will begin production at a new 90,000-liter manufacturing plant Oct. 5 located at its main plant in Incheon City
You may also be interested in...
Korea's Celltrion Not Seeking More Sales, Distribution Deals With Big Pharma
SEOUL - Seo Jung-Jin, CEO of South Korea's biosimilar front-runner Celltrion, Inc. said his company isn't looking to establish additional sales and distribution partnerships with Big Pharma
Korea's Celltrion Not Seeking More Sales, Distribution Deals With Big Pharma
SEOUL - Seo Jung-Jin, CEO of South Korea's biosimilar front-runner Celltrion, Inc. said his company isn't looking to establish additional sales and distribution partnerships with Big Pharma
Korea's Hanwha Chemical Leads With Enbrel Biosimilar - BIO Korea
Merck will develop and commercialize the biosimilar form of Enbrel - HD203 - in all markets except Korea and Turkey, where Hanwha retained marketing rights.